DG,
"I am not mad at you. I just think it is "too funny" the lengths that you are going to in order to correct up your previous thesis on Femprox. However, your need to hammer that point is tiring. The rest of us know what the score is on Femprox. And that score does not include your misinterpretation of what Pascoe told Eman. Not getting a deal does not mean that there was no solid interest...if you can follow triple negatives."
Really?
I don't know how I am supposed to correct being wrong. That's right wrong. I was wrong, wrong, wrong. For some reason I actually thought they would meet their own guidance and get a partner in the first half of 2014 or later in 2014. If there is a way for me to get into a time machine and go back let me know.
Eicoman, was awesome in sharing what he learned from talking with Pascoe... But I'm entitled to my own understanding of what was said. CEO's often use double speak with great skill. In this case that's what I feel was done.
Pascoe, tried to reassure a shareholder, but the reality is really smart biotech companies looked at Femprox and said no. The only reason they would not want it is if they looked at it and thought they were likely to lose money. We can say, well it's because APRI wants the US, or they want to see a competitor product approved first, and maybe I'm wrong again, but my gut says the real issue is they think Femprox was likely to fail if they invested in it.
I believe the science APRI has around Femprox is the main issue. Looking at the trials from China makes/made me nervous from the start but they kept moving forward, guidance from the FDA, and Europe and telling us to look for a potential partner deal in 2014. So I accepted they must have something. Again... ((((I WAS WRONG))))
So pardon me for pointing out, Femprox is_________. Fill in the blank.
Market Data 
Markets 
AI
